ATSE:BIOT

Stock Analysis Report

Executive Summary

Bioter S.A. operates as a construction company in Greece and internationally.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Share Price & News

How has Bioter's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

BIOT

4.5%

GR Construction

3.1%

GR Market


1 Year Return

-35.6%

BIOT

41.9%

GR Construction

26.0%

GR Market

Return vs Industry: BIOT underperformed the Greek Construction industry which returned 41.9% over the past year.

Return vs Market: BIOT underperformed the Greek Market which returned 26% over the past year.


Shareholder returns

BIOTIndustryMarket
7 Day0%4.5%3.1%
30 Day0.8%-2.7%0.7%
90 Day89.1%-0.3%1.7%
1 Year-35.6%-35.6%42.0%41.9%30.0%26.0%
3 Year-22.4%-22.4%112.4%96.5%57.8%44.0%
5 Year-69.8%-69.8%31.5%23.1%-77.2%-77.8%

Price Volatility Vs. Market

How volatile is Bioter's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bioter undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Bioter is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Bioter has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of BIOT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Bioter regulatory filings.
  • Explore potentially undervalued companies in the Capital Goods industry.

Future Growth

How is Bioter forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.1%

Forecasted Capital Goods industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bioter has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Bioter performed over the past 5 years?

-4.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: BIOT is unprofitable, and losses have increased over the past 5 years at a rate of -4.6% per year.

Accelerating Growth: Unable to compare BIOT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BIOT is unprofitable, making it difficult to compare its past year earnings growth to the Construction industry (8.1%).


Return on Equity

High ROE: BIOT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: BIOT is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: BIOT is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Bioter's financial position?


Financial Position Analysis

Short Term Liabilities: BIOT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: BIOT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: BIOT has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: BIOT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: BIOT has a low level of unsold assets or inventory.

Debt Coverage by Assets: BIOT has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BIOT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BIOT has less than a year of cash runway if free cash flow continues to reduce at historical rates of -9.5% each year


Next Steps

Dividend

What is Bioter's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.9%markettop25%3.8%industryaverage3.5%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate BIOT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BIOT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if BIOT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIOT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BIOT's dividend in 3 years as they are not forecast to pay a notable one for the Greek market.


Next Steps

Management

What is the CEO of Bioter's salary, the management and board of directors tenure and is there insider trading?


CEO

Georgios Mavroskotis Andrea 0

0yrs

Tenure

0

Mr. Georgios Mavroskotis tou Andrea serves as the Chief Executive Officer and General Manager of BIOTER S.A. and served its Managing Director. Mr. Andrea serves as Executive Vice-Chairman of BIOTER S.A. 


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Sell€80025 Jan 19
Georgios Mavroskotis Andrea
EntityIndividual
Role
Chief Executive Officer
Executive Vice-Chairman
Shares10,000
Max Price€0.08
Sell€2,10010 Jan 19
Georgios Mavroskotis Andrea
EntityIndividual
Role
Chief Executive Officer
Executive Vice-Chairman
Shares30,000
Max Price€0.07
Sell€1,96709 Jan 19
Georgios Mavroskotis Andrea
EntityIndividual
Role
Chief Executive Officer
Executive Vice-Chairman
Shares24,587
Max Price€0.08
Sell€1,20708 Jan 19
Georgios Mavroskotis Andrea
EntityIndividual
Role
Chief Executive Officer
Executive Vice-Chairman
Shares13,413
Max Price€0.09
Sell€70807 Jan 19
Georgios Mavroskotis Andrea
EntityIndividual
Role
Chief Executive Officer
Executive Vice-Chairman
Shares12,000
Max Price€0.059
Sell€1,60021 Dec 18
Georgios Mavroskotis Andrea
EntityIndividual
Role
Chief Executive Officer
Executive Vice-Chairman
Shares20,000
Max Price€0.08
Sell€1,60019 Dec 18
Georgios Mavroskotis Andrea
EntityIndividual
Role
Chief Executive Officer
Executive Vice-Chairman
Shares20,000
Max Price€0.08
Sell€1,60018 Dec 18
Georgios Mavroskotis Andrea
EntityIndividual
Role
Chief Executive Officer
Executive Vice-Chairman
Shares20,000
Max Price€0.08
Sell€2,16013 Dec 18
Georgios Mavroskotis Andrea
EntityIndividual
Role
Chief Executive Officer
Executive Vice-Chairman
Shares27,000
Max Price€0.08
Sell€3,50017 Oct 18
Georgios Mavroskotis Andrea
EntityIndividual
Role
Chief Executive Officer
Executive Vice-Chairman
Shares35,000
Max Price€0.10
Sell€2,70016 Oct 18
Georgios Mavroskotis Andrea
EntityIndividual
Role
Chief Executive Officer
Executive Vice-Chairman
Shares30,000
Max Price€0.09

Ownership Breakdown


Management Team

  • Ioannis Ioanni

    Executive Chairman

    • Tenure: 0yrs
  • Georgios Mavroskotis Andrea

    Executive Vice-Chairman

    • Tenure: 0yrs
  • Georgios Milingos

    Head of Accounting

    • Tenure: 0yrs

Board Members

  • Ioannis Ioanni

    Executive Chairman

    • Tenure: 0yrs
  • Michail Kyriakou

    Non-Executive Director

    • Tenure: 0yrs
  • Georgios Mavroskotis Andrea

    Executive Vice-Chairman

    • Tenure: 0yrs
  • Aristotelis Konstantinou

    Non-Executive Director

    • Tenure: 0yrs
  • Grigorios Georgiou

    Independent Non-Executive Director

    • Tenure: 0yrs
  • Athanasios Konstantinou

    Independent Non-Executive Director

    • Tenure: 0yrs
  • Georgios Aristoteli

    Independent Non-Executive Director

    • Tenure: 0yrs
  • Konstantinos Georgiou

    Independent Non-Executive Director

    • Tenure: 0yrs

Company Information

Bioter S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bioter S.A.
  • Ticker: BIOT
  • Exchange: ATSE
  • Founded: 1962
  • Industry: Construction and Engineering
  • Sector: Capital Goods
  • Market Cap: €1.012m
  • Shares outstanding: 16.73m
  • Website: https://www.bioter.gr

Location

  • Bioter S.A.
  • Eftychidou 45
  • Athens
  • 11634
  • Greece

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIOTATSE (The Athens Stock Exchange)YesOrdinary SharesGREURJan 1994

Biography

Bioter S.A. operates as a construction company in Greece and internationally. It is involved in the execution of various projects, such as roads, ports, industrial-energy, electromechanical-communications, ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 20:46
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.